Cost-Effectiveness Analysis of Dacomitinib versus Gefitinib in the First-Line Treatment of EGFR-Positive Advanced or Metastatic Non-Small Cell Lung Cancer-Reference-Cited by-同舟云学术

Cost-Effectiveness Analysis of Dacomitinib versus Gefitinib in the First-Line Treatment of EGFR-Positive Advanced or Metastatic Non-Small Cell Lung Cancer

Published:2021-05 Issue: Volume:Volume 13 Page:4263-4270
ISSN:1179-1322
Container-title:Cancer Management and Research
language:en
Short-container-title:CMAR

Author:

Zhang Longfeng,Li Na,Liu Maobai^ORCID,Zheng Bin,Wu Zhijuan,Cai Hongfu^ORCID

Publisher

Informa UK Limited

Subject

Oncology

Reference31 articles.

1. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

2. Revisiting Stage IIIB and IV Non-small Cell Lung Cancer

3. Target Binding Properties and Cellular Activity of Afatinib (BIBW 2992), an Irreversible ErbB Family Blocker

4. PF00299804, an Irreversible Pan-ERBB Inhibitor, Is Effective in Lung Cancer Models with EGFR and ERBB2 Mutations that Are Resistant to Gefitinib

5. U.S. Food & Drug Administration. FDA approves dacomitinib for metastatic non-small cell lung cancer. Available from: https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-dacomitinib-metastatic-non-small-cell-lung-cancer–0. Accessed August 10, 2020.

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Critical Examination of Modeling Approaches Used in Economic Evaluations of First-Line Treatments for Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutations: A Systematic Literature Review;PharmacoEconomics;2024-03-15

2. Cost‐effectiveness analysis of dinutuximab β for the treatment of high‐risk neuroblastoma in China;Pediatric Blood & Cancer;2023-09-16

3. The Cost-Effectiveness of Sugemalimab Plus Chemotherapy as First-Line Treatment for Metastatic Squamous and Non-squamous NSCLC in China;Advances in Therapy;2023-07-15

4. A systematic review of economic evaluations of tyrosine kinase inhibitors for non-small cell lung cancer (NSCLC);Expert Opinion on Pharmacotherapy;2022-07-04

5. PEGylated SLN as a Promising Approach for Lymphatic Delivery of Gefitinib to Lung Cancer;International Journal of Nanomedicine;2022-07